

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7363986

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ORTHOPEUTICS GROUP, LLC		04/25/2022
RECEIVING PARTY DATA		
Name:	SPINAL SIMPLICITY, LLC	
Street Address:	6363 COLLEGE BOULEVARD	
Internal Address:	SUITE 320	
City:	OVERLAND PARK	
State/Country:	KANSAS	
Postal Code:	66211	
PROPERTY NUMBERS Total: 15		
Property Type	Number	
Patent Number:	9084772	
Patent Number:	9101602	
Patent Number:	7435722	
Patent Number:	8153600	
Patent Number:	8022101	
Patent Number:	8211938	
Patent Number:	10278947	
Patent Number:	10980771	
Patent Number:	8450276	
Patent Number:	8119599	
Patent Number:	8198248	
Patent Number:	8283322	
Patent Number:	9192507	
Patent Number:	9918870	
Patent Number:	9492592	
CORRESPONDENCE DATA		
Fax Number:	(913)777-5601	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		

PATENT

Phone: (913) 777-5600
Email: patents@eriseip.com
Correspondent Name: ERISE IP, P.A.
Address Line 1: 7015 COLLEGE BOULEVARD
Address Line 2: SUITE 700
Address Line 4: OVERLAND PARK, KANSAS 66211

ATTORNEY DOCKET NUMBER:	2704-1.17
--------------------------------	-----------

NAME OF SUBMITTER:	JENNIFER C. BAILEY
---------------------------	--------------------

SIGNATURE:	/Jennifer C. Bailey/
-------------------	----------------------

DATE SIGNED:	06/03/2022
---------------------	------------

Total Attachments: 10

source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page1.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page2.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page3.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page4.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page5.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page6.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page7.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page8.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page9.tif
source=Patent_Assignment_Ortho_Grp_to_SS_as_Filed#page10.tif

EXHIBIT C

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT is made by and between Orthopeutics Group, LLC, a Kentucky corporation, having a place of business at 2284 Savannah Lane, Lexington, Kentucky 40513 ("Assignor"); and Spinal Simplicity, LLC, a Kansas corporation, having a place of business at 6363 College Boulevard, Suite 320, Overland Park, Kansas 66211 ("Assignee").

WHEREAS, Assignor owns the entire right, title, and interest in the patents and patent applications listed in Exhibit A (the "Patent(s)");

WHEREAS, Assignee is desirous of acquiring Assignor's entire right, title, and interest in and to the Patent(s), including the right to sue for and collect past and future damages for patent infringement throughout the world; and


WHEREAS, Assignor is desirous of and willing to grant to Assignee its entire right, title, and interest in and to the Patent(s).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns, grants, transfers, and otherwise conveys to Assignee its entire right, title, and interest in and to the Patent(s), the inventions and technology set forth and described in the Patent(s), and any and all divisions, continuations, continuations-in-part, reissues, reviews, reexaminations, renewals, and extensions of the Intellectual Property (collectively "Patent Properties"). Such assignment expressly includes the right to sue for and collect past and future damages for patent infringement of the Patent Properties throughout the world. It is the intent of the Parties that such assignment of the entire right, title, and interest of the Patent Properties is to be held and enjoyed by Assignee for its own use and behoof, and for its successors, assigns, and legal representatives, as fully and entirely as the same would have been held by Assignor had this assignment and transfer not been made.

Assignor represents and warrants that as of the Effective Date of this Assignment, it has the full right to convey the interests herein assigned and that it has not executed any agreement in conflict herewith.

IN TESTIMONY WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representative.

Orthopeutics Group, LLC (Assignor)

By: 

Printed Name: Dale Williams

Date: April 25, 2022

Title: MANAGER

NOTARY CERTIFICATE

State of Kentucky)
County of Fayette) ss.


The foregoing Patent Assignment was signed or acknowledged before me on this 25th day of April, 2022, by Dale Williams.

WITNESS my hand and official seal.

(SEAL)

Howard Keith Justice
Notary Public

My Commission Expires: 04-04-2024



Spinal Simplicity, LLC hereby declares it accepts the rights and property hereby assigned and transferred to it.

Spinal Simplicity, LLC (Assignee)

By: Tim McCown

Printed Name: Timothy J. McCown

Date: April 25, 2022

Title: COO

EXHIBIT A

	Patent Application No. / Patent No.	Status	Filing Date	Issue Date	Country	Title
1	7,435,722	Issued	2/24/2004	10/14/2008	US	Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
2	8,022,101	Issued	2/28/2007	9/20/2011	US	Method of treating a knee meniscus with a cross-linking reagent to increase resistance to tearing or rupturing
3	8,119,599	Issued	10/17/2007	2/21/2012	US	Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
4	8,153,600	Issued	2/2/2006	8/29/2012	US	Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity
5	8,198,248	Issued	9/3/2008	6/12/2012	US	Formulations for Nonsurgical Exogenous Crosslink Therapy
6	8,211,938	Issued	3/2/2010	7/3/2012	US	DIRECT APPLICATION OF NON-TOXIC CROSSLINKING REAGENTS TO RESIST PROGRESSIVE SPINAL

						DEGENERATION AND DEFORMITY
7	8,283,322	Issued	7/1/2009	10/9/2012	US	Formulations for Nonsurgical Exogenous Crosslink Therapy
8	8,450,276	Issued	6/16/2010	5/28/2013	US	Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
9	9,084,772	Issued	8/29/2002	7/21/2015	US	Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
10	9,101,602	Issued	12/13/2010	8/11/2015	US	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES
11	9,192,507	Issued	12/13/2012	11/24/2015	US	TISSUE CROSSLINKING FOR TREATMENT OF SNORING AND OBSTRUCTIVE SLEEP APNEA

12	9,492,592	Issued	4/13/2015	11/15/2016	US	CROSSLINKER ENHANCED REPAIR OF KNEE MENISCUS
13	9,918,870	Issued	9/29/2015	3/20/2018	US	TISSUE CROSSLINKING FOR TREATMENT OF SNORING AND OBSTRUCTIVE SLEEP APNEA
14	10,278,947	Issued	2/12/2014	5/7/2019	US	CROSSLINKER ENHANCED REPAIR OF CONNECTIVE TISSUES
15	10,980,771	Issued	10/26/2018	4/20/2021	US	Crosslinker enhanced repair of connective tissues
16	2002335683	Issued	8/29/2002	8/29/2002	AU	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES
17	2004268628	Issued	8/27/2004	8/27/2004	AU	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
18	2010266306	Issued	6/30/2010	6/30/2010	AU	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
19	2,458,821	Issued	8/29/2002	1/20/2012	CA	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE

						RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES
20	2,536,415	Issued	8/27/2004	7/23/2013	CA	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
21	2,770,153	Issued	6/30/2010	7/24/2018	CA	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
22	1660001	Issued	8/27/2004	10/9/2019	EU	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
	1660001	Issued	8/27/2004	10/9/2019	EU-DE	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
	1660001	Issued	8/27/2004	10/9/2019	EU-FR	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
	1660001	Issued	8/27/2004	10/9/2019	EU-GB	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
23	2448568	Issued	6/30/2010	1/3/2018	EU-AT	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY

	2448568	Issued	6/30/2010	1/3/2018	EU-BE	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-CH	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-DE	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-DK	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-ES	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-FI	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-FR	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-GB	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-IE	FORMULATIONS FOR NONSURGICAL

						EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-IT	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-NL	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-NO	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
	2448568	Issued	6/30/2010	1/3/2018	EU-SE	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
24	1432312	Issued	8/29/2002	1/9/2019	EU-DE	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES
	1432312	Issued	8/29/2002	1/9/2019	EU-FR	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER

						COLLAGENOUS TISSUES
	1432312	Issued	8/29/2002	1/9/2019	EU-GB	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES
25	344482	Issued	6/30/2010	8/19/2020	IN	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
26	4955398	Issued	8/27/2004	3/23/2012	JP	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
27	101238647	Issued	8/27/2004	2/21/2013	KR	CROSSLINKING REAGENT FOR TREATING VERTEBRAL DISC DISORDERS
28	165591-A	Issued	6/30/2010	4/6/2018	MY	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
29	178218	Issued	6/30/2010	7/18/2014	SG	FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY
30	516602.2 (App.#)	Abandoned	8/29/2002		HK	USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE

						RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES
31	93125979 (App.#)	Pending	8/27/2004		TW	Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability